Literature DB >> 3258675

In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis.

M Müller1, J G Lossick, T E Gorrell.   

Abstract

We have identified Trichomonas vaginalis strains resistant in vitro to metronidazole, especially under aerobic conditions. Since little is known about the relationship of treatment outcome to metronidazole susceptibility of T. vaginalis, we studied the aerobic and anaerobic susceptibility to metronidazole of 310 clinical isolates of T. vaginalis. Of 199 patients with known outcomes after metronidazole treatment for vaginal trichomoniasis, the geometric mean minimal lethal concentration (MLC) under aerobic conditions for trichomonads associated with cases cured by a single 2-g dose was 24.1 micrograms/ml (n = 146), while that of treatment-resistant isolates (n = 53) was 195.5 micrograms/ml. The corresponding mean anaerobic MLC values were 1.6 and 5.05 micrograms/ml, respectively. The average aerobic:anaerobic MLC ratio was about twofold higher for the resistant isolates. Treatment resistance was more frequent at aerobic MLC values of greater than 25 micrograms/ml or anaerobic values of greater than 1.6 micrograms/ml. Although there was overlap of the metronidazole susceptibility distribution of susceptible and resistant isolates, significant resistance to treatment was common when isolates of T. vaginalis had aerobic MLC values of greater than 100 micrograms/ml or anaerobic MLC values of greater than 3.1 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258675     DOI: 10.1097/00007435-198801000-00004

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  20 in total

1.  Managing Resistant Trichomonas Vaginitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.

Authors:  T Meri; T S Jokiranta; L Suhonen; S Meri
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis.

Authors:  Andrea L Crowell; Kolby A Sanders-Lewis; W Evan Secor
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

4.  Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole.

Authors:  Jane R Schwebke; Frank J Barrientes
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

5.  The laboratory diagnosis of Trichomonas vaginalis.

Authors:  Gary E Garber
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-01       Impact factor: 2.471

6.  In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.

Authors:  E M Narcisi; W E Secor
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 7.  Clinical and microbiological aspects of Trichomonas vaginalis.

Authors:  D Petrin; K Delgaty; R Bhatt; G Garber
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 8.  Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Authors:  Sarah L Cudmore; Kiera L Delgaty; Shannon F Hayward-McClelland; Dino P Petrin; Gary E Garber
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Trichomonas vaginalis contact-dependent cytolysis of epithelial cells.

Authors:  Gila Lustig; Christopher M Ryan; W Evan Secor; Patricia J Johnson
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

10.  Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis.

Authors:  D V Quon; C E d'Oliveira; P J Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.